Clinical Trial

A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Angiokeratomas (LOTU)

Name: A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Angiokeratomas (LOTU) — clinical trial record (NCT07552077)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: LOTU

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

The purpose of this study is to evaluate the safety and effectiveness of the experimental drug PTX-022 in the treatment of angiokeratomas

Trial Details

NCT Number	NCT07552077
Lead Sponsor	Palvella Therapeutics, Inc.
Conditions	Angiokeratomas
Enrollment	15 participants
Start Date	2026-04
Primary Completion	2027-08 (estimated)
Study Completion	2027-09 (estimated)
Updated on ClinicalTrials.gov	2026-04-27